Pharmacokinetic studies with PET

Progress in Drug Research

Volumn 62, Issue , 2005, Pages 279-317

  Bergström, Mats ^a,b   Långström, Bengt ^a,b  

^a BIACORE AB   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; FLUORINE 18; RADIOACTIVE MATERIAL; RADIOISOTOPE; TECHNETIUM 99M; VINPOCETINE;

ACCURACY; BIOPSY; CELLULAR DISTRIBUTION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONCENTRATION (PARAMETERS); DNA SYNTHESIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG LABELING; DRUG METABOLISM; DRUG UPTAKE; FOLLOW UP; HUMAN; ISOTOPE LABELING; KINETICS; LUMBAR PUNCTURE; MATHEMATICAL MODEL; MEDICAL INFORMATION; METHODOLOGY; MICRODIALYSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARMACOLOGICAL PARAMETERS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION RESPONSE; RADIOACTIVITY; REVIEW; SCINTIGRAPHY; SURGICAL TECHNIQUE; VALIDATION PROCESS;

EID: 27644469954     PISSN: 0071786X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/3-7643-7426-8_8     Document Type: Review

References (72)

1. Aboagye EO, Price PM, Jones T (2001) In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography. Drug Discov Today 6: 293-302
2. Fischman AJ, Alpert NM, Babich JW, Rubin RH (1997) The role of positron emission tomography in pharmacokinetic analysis. Drug Metab Rev 29: 923-956
3. Fischman AJ, Alpert NM, Rubin RH (2002) Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action. Clin Pharmacokinet 41: 581-602
4. Gupta N, Price PM, Aboagye EO (2002) PET for in vivo pharmacokinetic and pharmacodynamic measurements. Eur J Cancer 38: 2094-2107
5. Hutchinson OC, Collingridge DR, Barthel H, Price PM, Aboagye EO (2003) Pharmacokinetics of radiolabeled anticancer drugs for positron emission tomography. Curr Pharm Des 9: 917-929
6. Klimas MT (2002) Positron emission tomography and drug discovery: contributions to the understanding of pharmacokinetics, mechanism of action and disease state characterization. Mol Imaging Biol 4: 311-337
7. Propper DJ, de Bono J, Saleem A, Ellard S, Flanagan E, Paul J, Ganesan TS, Talbot DC, Aboagye EO, Price P et al (2003) Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000. J Clin Oncol 21: 203-210
8. Roselt P, Meikle S, Kassiou M (2004) The role of positron emission tomography in the discovery and development of new drugs; as studied in laboratory animals. Eur J Drug Metab Pharmacokinet 29: 1-6
9. Rubin RH, Fischman AJ (1997) Positron emission tomography in drug development. Q J Nucl Med 41: 171-175
10. Bergstrom M, Awad R, Estrada S, Malman J, Lu L, Lendvai G, Bergstrom-Pettermann E, Langstrom B (2003) Autoradiography with positron emitting isotopes in positron emission tomography tracer discovery. Mol Imaging Biol 5: 390-396
11. Bergstrom M, Bonasera TA, Lu L, Bergstrom E, Backlin C, Juhlin C, Langstrom B (1998) In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors. J Nucl Med 39:982-989
12. Bergstrom M, Westerberg G, Langstrom B (1997) 11C-harmine as a tracer for monoamine oxidase A (MAO-A): in vitro and in vivo studies. Nucl Med Biol 24: 287-293
13. Bergstrom M, Westerberg G, Kihlberg T, Langstrom B (1997) Synthesis of some 11C-labeled MAO-A inhibitors and their in vivo uptake kinetics in rhesus monkey brain. Nucl Med Biol 24: p. 381-388
14. Stahl M, Bouw R, Jackson A, Pay V (2002) Human microdialysis. Curr Pharm Biotechnol 3:165-178
15. Ederoth P, Tunblad K, Bouw R, Lundberg CJ, Ungerstedt U, Nordstrom CH, Hammarlund-Udenaes M (2004) Blood-brain barrier transport of morphine in patients with severe brain trauma. Br J Clin Pharmacol 57: 427-435
16. Bielecka-Grzela S, Klimowicz A (2003) Application of cutaneous microdialysis to evaluate metronidazole and its main metabolite concentrations in the skin after a single oral dose. J Clin Pharm Ther 28: 465-469
17. Joukhadar C, Stass H, Muller-Zellenberg U, Lackner E, Kovar F, Minar E, Muller M (2003) Penetration of moxifloxacin into healthy and inflamed subcutaneous adipose tissues in humans. Antimicrob Agents Chemother 47: 3099-3103
18. Joukhadar C, Klein N, Dittrich P, Zeitlinger M, Geppert A, Skhirtladze K, Frossard M, Heinz G, Muller M (2003) Target site penetration of fosfomycin in critically ill patients. J Antimicrob Chemother 51: 1247-1252
19. Langstrom B, Kihlberg T, Bergstrom M, Antoni G, Bjorkman M, Forngren BH, Forngren T, Hartvig P, Markides K, Yngve U, Ogren M (1999) Compounds labeled with short-lived beta(+)-emitting radionuclides and some applications in life sciences. The importance of time as a parameter. Acta Chem Scand 53: 651-669
20. Beshara S, Lundqvist H, Sundin J, Lubberink M, Tolmachev V, Valind S, Antoni G, Langstrom B, Danielson BG (1999) Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography. Br J Haematol 104: 296-302
21. Fischman AJ, Livni E, Babich JW, Alpert NM, Bonab A, Chodosh S, McGovern F, Kamitsuka P, Liu YY, Cleeland R et al (1996) Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography. Antimicrob Agents Chemother 40: 659-664
22. Fischman AJ, Babich JW, Bonab AA, Alpert NM, Vincent J, Callahan RJ, Correia JA, Rubin RH (1998) Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. Antimicrob Agents Chemother 42: 2048-2054
23. Gulyas B, Halldin C, Karlsson P, Chou YH, Swahn CG, Bonock P, Paroczai M, Farde L (1999) Brain uptake and plasma metabolism of [11C]vinpocetine: a preliminary PET study in a cynomolgus monkey. J Neuroimaging 9: 217-222
24. Gulyas B, Halldin C, Sandell J, Karlsson P, Sovago J, Karpati E, Kiss B, Vas A, Cselenyi Z, Farde L (2002) PET studies on the brain uptake and regional distribution of [11C]vinpocetine in human subjects. Acta Neurol Scand 106: 325-332
25. Islinger F, Bouw R, Stahl M, Lackner E, Zeleny P, Brunner M, Muller M, Eichler HG, Joukhadar C (2004) Concentrations of gemifloxacin at the target site in healthy volunteers after a single oral dose. Antimicrob Agents Chemother 48: 4246-4249
26. Lee Z, Berridge MS, Finlay WH, Heald DL (2000) Mapping PET-measured triamcinolone acetonide (TAA) aerosol distribution into deposition by airway generation. Int J Pharm 199:7-16
27. Matarrese M, Salimbeni A, Turolla EA, Turozzi D, Moresco RM, Poma D, Magni F, Todde S, Rossetti C, Sciarrone MT et al (2004) 11C-Radiosynthesis and preliminary human evaluation of the disposition of the ACE inhibitor [11C]zofenoprilat. Bioorg Med Chem 12: 603-611
28. Noda A, Takamatsu H, Murakami Y, Yajima K, Tatsumi M, Ichise R, Nishimura S (2003) Measurement of brain concentration of FK960 for development of a novel antidementia drug: a PET study in conscious rhesus monkeys. J Nucl Med 44: 105-108
29. Osman S, Rowlinson-Busza G, Luthra SK, Aboagye EO, Brown GD, Brady F, Myers R, Gamage SA, Denny WA, Baguley BC, Price PM (2001) Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and DNA-intercalating analogues. Cancer Res 61: 2935-2944
30. Rubin RH, Livni E, Babich J, Alpert NM, Liu YY, Tham E, Prosser B, Cleeland R, Callahan RJ, Correia JA et al (1993) Pharmacokinetics of fleroxacin as studied by positron emission tomography and [18F]fleroxacin. Am J Med 94: 31S-37S
31. Saleem A, Harte RJ, Matthews JC, Osman S, Brady F, Luthra SK, Brown GD, Blechen N, Connors T, Jones T et al (2001) Pharmacokinetic evaluation of N-[2-(dimethylamino) ethyl] acridine-4-carboxamide in patients by positron emission tomography. J Clin Oncol 19:1421-1429
32. Sanderson L, Taylor GW, Aboagye EO, Alao JP, Latigo JR, Coombes RC, Vigushin DM (2004) Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin a after intraperitoneal administration to mice. Drug Metab Dispos 32: 1132-1138
33. Bergstrom M, Nordberg A, Lunell E, Antoni G, Langstrom B (1995) Regional deposition of inhaled 11C-nicotine vapor in the human airway as visualized by positron emission tomography. Clin Pharmacol Ther 57: 309-317
34. Bergstrom M, Cass LM, Valind S, Westerberg G, Lundberg EL, Gray S, Bye A, Langstrom B (1999) Deposition and disposition of [11C]zanamivir following administration as an intranasal spray. Evaluation with positron emission tomography. Clin Pharmacokinet 36, Suppl 1:33-39
35. Berridge MS, Heald DL, Muswick GJ, Leisure GP, Voelker KW, Miraldi F (1998) Biodistribution and kinetics of nasal carbon-11-triamcinolone acetonide. J Nucl Med 39: 1972-1977
36. Berridge MS, Lee Z, Heald DL (2000) Regional distribution and kinetics of inhaled pharmaceuticals. Curr Pharm Des 6: 1631-1651
37. Berridge MS, Lee Z, Heald DL (2000) Pulmonary distribution and kinetics of inhaled [11C]triamcinolone acetonide. J Nucl Med 41: 1603-1611
38. Dolovich MB (2001) Measuring total and regional lung deposition using inhaled radio-tracers. J Aerosol Med 14, Suppl 1: S35-S44
39. Lee Z, Berridge MS (2002) PET imaging-based evaluation of aerosol drugs and their delivery devices: nasal and pulmonary studies. IEEE Trans Med Imaging 21: 1324-1331
40. Pike VW, Aigbirhio FI, Freemantle CA, Page BC, Rhodes CG, Waters SL, Jones T, Olsson P, Ventresca GP, Tanner RJ et al (1995) Disposition of inhaled 1,1,1,2-tetrafluoroethane (HFA134A) in healthy subjects and in patients with chronic airflow limitation. Measurement by 18F-labeling and whole-body gamma-counting. Drug Metab Dispos 23: 832-839
41. Nilsson D, Lennernas H, Fasth KJ, Sundin A, Tedroff J, Aquilonius SM, Hartvig P, Langstrom B (1999) Absorption of L-DOPA from the proximal small intestine studied in the rhesus monkey by positron emission tomography. Eur J Pharm Sci 7: 185-189
42. Gulyas B, Halldin C, Sovago J, Sandell J, Cselenyi Z, Vas A, Kiss B, Karpati E, Farde L (2002) Drug distribution in man: a positron emission tomography study after oral administration of the labeled neuroprotective drug vinpocetine. Eur J Nucl Med Mol Imaging 29: 1031-1038
43. Lappin G, Garner RC (2003) Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov 2: 233-240
44. Bergstrom M, Grahnen A, Langstrom B (2003) Positron emission tomography micro-dosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 59: 357-366
45. Meikle SR, Matthews JC, Brock CS, Wells P, Harte RJ, Cunningham VJ, Jones T, Price P (1998) Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study. Cancer Chemother Pharmacol 42: 183-193
46. Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ, Frackowiak RS (1996) Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab 16: 42-52
47. Lammertsma AA, Bench CJ, Price GW, Cremer JE, Luthra SK, Turton D, Wood ND, Frackowiak RS (1991) Measurement of cerebral monoamine oxidase B activity using L-[11C] deprenyl and dynamic positron emission tomography. J Cereb Blood Flow Metab 11: 545-556
48. Hume SP, Ashworth S, Opacka-Juffry J, Ahier RG, Lammertsma AA, Pike VW, Cliffe IA, Fletcher A, White AC (1994) Evaluation of [O-methyl-3H] WAY-100635 as an in vivo radioligand for 5-HT1A receptors in rat brain. Eur J Pharmacol 271: 515-523
49. Seltzer MA, Jahan SA, Sparks R, Stout DB, Satyamurthy N, Dahlbom M, Phelps ME, Barrio JR (2004) Radiation dose estimates in humans for (11)C-acetate whole-body PET. J Nucl Med 45: 1233-1236
50. Tang G, Tang X, Wang M, Luo L, Gan M (2004) Radiation dosimetry of O-(3-[18F]fluoropropyl)-L-tyrosine as oncologic PET tracer based on the mice distribution data. Appl Radiat Isot 60: 27-32
51. Pauleit D, Floeth F, Herzog H, Harnacher K, Tellmann L, Muller HW, Coenen HH, Langen KJ (2003) Whole-body distribution and dosimetry of O-(2-[18F]fluoroethyl)-L-tyrosine. Eur J Nucl Med Mol Imaging 30: 519-524
52. Marthi K, Hansen SB, Jakobsen S, Bender D, Smith SB, Smith DF (2003) Biodistribution and radiation dosimetry of [N-methyl-11C]mirtazapine, an antidepressant affecting adrenoceptors. Appl Radiat Isot 59:175-179
53. Aboagye EO, Luthra SK, Brady F, Poole K, Anderson H, Jones T, Boobis A, Burtles SS, Price P (2002) Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients. Br J Cancer 86: 1052-1056
54. Combes RD, Berridge T, Connelly J, Eve MD, Garner RC, Toon S, Wilcox P (2003) Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing. Eur J Pharm Sci 19: 1-11
55. Farde L, Hall H, Pauli S, Halldin C (1995) Variability in D2-dopamine receptor density and affinity: a PET study with [11C]raclopride in man. Synapse 20: 200-208
56. Bergstrom M, Fasth KJ, Kilpatrick G, Ward P, Cable KM, Wipperman MD, Sutherland DR, Langstrom B (2000) Brain uptake and receptor binding of two [11C]labeled selective high affinity NK1-antagonists, GR203040 and GR205171-PET studies in rhesus monkey. Neuropharmacology 39: 664-670
57. Dobbs FR, Banks W, Fleishaker JC, Valentine AD, Kinsey BM, Franceschini MP, Digenis GA, Tewson TJ (1995) Studies with [11C]alprazolam: an agonist for the benzodiazepine receptor. Nucl Med Biol 22: 459-466
58. Lahteenmaki P, Heikinheimo O, Croxatto H, Spitz I, Shoupe D, Birgerson L, Luukkainen T (1987) Pharmacokinetics and metabolism of RU 486. J Steroid Biochem 27: 859-863
59. Elsinga PH, Franssen EJ, Hendrikse NH, Fluks L, Weemaes AM, van der Graaf WT, de Vries EG, Visser GM, Vaalburg W (1996) Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET. J Nucl Med 37: 1571-1575
60. Elsinga PH, Hendrikse NH, Bart J, Vaalburg W, van Waarde A (2004) PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Des 10: 1493-1503
61. Kurdziel KA, Kiesewetter DO, Carson RE, Eckelman WC, Herscovitch P (2003) Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates. J Nucl Med 44: 1330-1339
62. Sundin A, Eriksson B, Bergstrom M, Bjurling P, Lindner KJ, Oberg K, Langstrom B (2000) Demonstration of [11C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography. Nucl Med Biol 27: 33-41
63. Bergstrom M, Eriksson B, Oberg K, Sundin A, Ahlstrom H, Lindner KJ, Bjurling P, Langstrom B (1996) In vivo demonstration of enzyme activity in endocrine pancreatic tumors: decarboxylation of carbon-11-DOPA to carbon-11-dopamine. J Nucl Med 37: 32-37
64. Saleem A, Brown GD, Brady F, Aboagye EO, Osman S, Luthra SK, Ranicar AS, Brock CS, Stevens MF, Newlands E et al (2003) Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res 63: 2409-2415
65. Luurtsema G, de Lange EC, Lammertsma AA, Franssen EJ (2004) Transport across the blood-brain barrier: stereoselectivity and PET-tracers. Mol Imaging Biol 6: 306-318
66. Rahman O, Kihlberg T, Langstrom B (2004) Synthesis of [11C]/(13C)amines via carbonylation followed by reductive amination. Org Biomol Chem 2: 1612-1616
67. Itsenko O, Kihlberg T, Langstrom B (2004) Photoinitiated carbonylation with [11C]carbon monoxide using amines and alkyl iodides. J Org Chem 69: 4356-4360
68. Karimi F, Langstrom B (2003) Synthesis of 11C-amides using [11C]carbon monoxide and in situ activated amines by palladium-mediated carboxaminations. Org Biomol Chem 1: 541-546
69. Kihlberg T, Karimi F, Langstrom B (2002) [(11)C] Carbon monoxide in selenium-mediated synthesis of (11)C-carbamoyl compounds. J Org Chem 67: 3687-3692
70. Rahman O, Kihlberg T, Langstrom B (2003) Aryl triflates and [11C]/(13C)carbon monoxide in the synthesis of 11C-/13C-amides. J Org Chem 68: 3558-3562
71. Farde L, Ginovart N, Ito H, Lundkvist C, Pike VW, McCarron JA, Halldin C (1997) PET-characterization of [carbonyl-11C]WAY-100635 binding to 5-HT1A receptors in the primate brain. Psychopharmacology (Berl) 133: 196-202
72. Olsson H, Halldin C, Farde L (2004) Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET. Neuroimage 22: 794-803